Programmaschema Chicago op Schier 2023 – dinsdag 6 juni
zie hyperlinks hieronder voor de vervolgdagen
Dinsdag 6 juni 2023
08.30 uur Virtual ASCO – Locatie: Dorpshuis
Educational: Prioritizing and sequencing for advanced prostate cancer
- N. Agarwal When More Is More: Treatment Intensification for Hormone-Sensitive Prostate Cancer
- A. Hamid When Less Is More: Decreasing Exposure to Systemic Therapy for Hormone-Sensitive Prostate Cancer
Educational: Management of prostate cancer in older adults
- A. Morgans Applying Risk/Benefit Considerations for Elder Patients to Current Treatment Advances in Prostate Cancer
Educational: bringing new drugs in oncology: Incorporation into practice
- K. Fizazi Taking Radioligands to the Next Level: Targeting PSMA with Lutetium 177
Oral Abstract Session Genitourinary Cancer—Prostate + discussants (zondag 04-06 08.00-11.00)
- A. Bossi Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2×2 design Abs#LBA5000
- K. Fizazi TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations Abs#5004
10.00 uur Pauze
10.15 uur Virtual ASCO – Locatie: Dorpshuis
Educational Managing a long and winding road: ER-positive breast cancer
N. Turner Using CDK4/6 Inhibitor in Early Stage and Advanced HR+ Breast Cancer
Oral abstract session breast cancer local/adjuvant
- D. Slamon Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: Primary results from the phase III NATALEE trial Abs#LBA500
- E. Hamilton Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC) Abs#501
- N. Harbeck Cyclin’ Through the Inhibitors Abstracts discussant
- Z. Jiang TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC) Abs#LBA1013
Educational: Improving quality of life on chemotherapy for patients with breast cancer: realistic of wishful thinking?
M. Accordino Mitigating Neuropathy: Cooling Down and Other Options
Poster session Colorectal maandag
Miriam Koopman Upfront palliative resection of primary tumor versus no resection in patients with synchronous metastatic colorectal cancer: The randomized phase 3 CAIRO4 study of the Dutch Colorectal Cancer Group (DCCG. Abs#3517
A. Kim The Evolving Role of Surgery in Advanced Colorectal Cancer
12.00 -14:00 uur pauze – Lunch, Havenpaviljoen Wad Anderz, Reeweg 25
14.00 uur Virtual ASCO, locatie: Dorpshuis
Educational: A juggling act: Managing the toxicity of estrogen deprivation for patients with breast cancer
- Rojas Better Sexual Health for Female Patients on Endocrine Therapy: Strategies Across the Age Spectrum
- Woodard Innovations in Fertility: Are We Where We Want to Be?
Oral abstract session breast cancer metastatic
- E. Hamilton A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC) Abs#1004
- I. Krop An age-specific pooled analysis of trastuzumab deruxtecan (T‑DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03 Abs#1006
14.45-15.00 uur Pauze
- S. Tolaney Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC) Abs#1003
- Q. Khan Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial Abs#1007
- Gabe Sonke Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) Abs#LBA1000
- A. Llombart Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial Abs# 1001
- D. Stover Seeking Sensitivity and Resisting Resistance: Learning From the CDK4/6 Experience Abstracts discussant
16.30 uur: Live verbinding met Chicago – Gabe Sonke
17.30 uur Pauze + teruglopen naar Van der Werff
17.45 uur Klinische implicaties olv referent (besloten) – Locatie: vd Werff
18.30 uur Einde middagprogramma
19.30 uur BBQ in Beachclub Noderstraun, Badweg 32